Morgan Stanley lifts target for BeOne Medicines stock to USD 425.00

Published on 10/17/2026 at 20:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

June-quarter revenue was USD 1.71 billion. BeOne Medicines stock cost USD 369.06 on October 16, 2026, down 1.34 percent versus Nasdaq's prior close.

Analyst view and dates

On October 16, 2026, Morgan Stanley lifted its BeOne Medicines target to USD 425.00.
June-quarter revenue reached USD 1.71 billion.
BeOne Medicines stock was last at USD 369.06 on October 16, 2026 at 4:00 p.m. ET, down 1.34 percent versus the Nasdaq prior close.
BeOne Medicines is scheduled to report third-quarter results on November 10, 2026.

ONC, US07725L1026, Illustration mit AI erstellt.

BeOne Medicines (ISIN US07725L1026) has a fresh analyst target of USD 425.00. According to Markets Insider on October 16, 2026, Morgan Stanley raised its target from USD 405.00 and kept an Overweight rating. The new target is 15.16 percent above the Nasdaq price of USD 369.06. BeOne Medicines was last at USD 369.06 on October 16, 2026 at 4:00 p.m. ET, down 1.34 percent versus the Nasdaq prior close of USD 374.08.

Revenue reached USD 1.71 billion

The latest reported operating figure remains the second quarter ended June 30, 2026. Markets Insider reported quarterly revenue of USD 1.71 billion and net income of USD 237.01 million. Revenue was up 29.55 percent from USD 1.32 billion a year earlier, while net income rose 151.37 percent from USD 94.32 million.

Stock stays below its yearly high

The Nasdaq price sat 4.19 percent below the 52-week high of USD 385.22 on October 16, 2026. Its 52-week low was USD 253.95, while the same session's range ran from USD 367.35 to USD 375.30. Trading volume reached 422,233 shares against an average of 386,796.

The company had a market capitalization of USD 39.4 billion and a trailing P/E ratio of 26.54 on October 16, 2026. Simply Wall St listed November 10, 2026 as the date for BeOne Medicines to report third-quarter results.

Comparison with peers

BeOne Medicines (Nasdaq, USD): minus 1.34 percent, P/E 26.54, market capitalization USD 39.4 billion.

Gilead Sciences (Nasdaq, USD): minus 0.75 percent, P/E minus 58.50, market capitalization USD 193.7 billion.

Amgen (Nasdaq, USD): minus 0.35 percent, P/E 26.88, market capitalization USD 233.8 billion.

Valuation and reporting date

For investors, the analyst target and the upcoming reporting date are the clearest near-term reference points. The target remains above the latest Nasdaq price, while the next report is scheduled for November 10, 2026.

Price remains below the high

BeOne Medicines was last at USD 369.06 on Nasdaq on October 16, 2026 at 4:00 p.m. ET, down 1.34 percent versus the Nasdaq prior close of USD 374.08. The price was 4.19 percent below the 52-week high of USD 385.22.